Literature DB >> 11979126

Current status and future prospects of the Global Lymphatic Filariasis Programme.

D H Molyneux1, M J Taylor.   

Abstract

Lymphatic filariasis is recognized as one of the world's most disabling diseases. Adult lymphatic filarial nematodes live for several years; they infest the lymphatic and blood systems, and are transmitted via mosquito vectors. Acute and chronic disease can develop, manifesting as acute inflammation, hydrocoele, lymphoedema and elephantiasis. The development of a global programme for the elimination of lymphatic filariasis (focusing on disease caused by Wuchereria bancrofti) followed a resolution by the World Health Assembly in 1997 that endemic countries should develop programmes to eliminate lymphatic filariasis as a public health problem. This developed from an earlier recommendation by the International Task Force for Disease Eradication in 1993 that lymphatic filariasis was one of six diseases that could, in theory, be eradicated. Herein we review the current status and future prospects of the Global Lymphatic Filariasis Programme, which was launched in 2000.

Entities:  

Mesh:

Year:  2001        PMID: 11979126     DOI: 10.1097/00001432-200104000-00008

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  17 in total

1.  Update on Lymphatic Filarial Infections.

Authors:  Paul B. Keiser; Thomas B. Nutman
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

2.  Cloning and characterization of high mobility group box protein 1 (HMGB1) of Wuchereria bancrofti and Brugia malayi.

Authors:  Sivasakthivel Thirugnanam; Gnanasekar Munirathinam; Anandharaman Veerapathran; Gajalakshmi Dakshinamoorthy; Maryada V Reddy; Kalyanasundaram Ramaswamy
Journal:  Parasitol Res       Date:  2012-03-09       Impact factor: 2.289

3.  Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production.

Authors:  Achim Hoerauf; Sabine Mand; Kerstin Fischer; Thomas Kruppa; Yeboah Marfo-Debrekyei; Alexander Yaw Debrah; Kenneth M Pfarr; Ohene Adjei; Dietrich W Büttner
Journal:  Med Microbiol Immunol       Date:  2003-03-05       Impact factor: 3.402

4.  Thioredoxin from Brugia malayi: defining a 16-kilodalton class of thioredoxins from nematodes.

Authors:  Kannan Kunchithapautham; B Padmavathi; R B Narayanan; P Kaliraj; Alan L Scott
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

Review 5.  The use of molecular xenomonitoring for surveillance of mosquito-borne diseases.

Authors:  Mary M Cameron; Anita Ramesh
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-12-28       Impact factor: 6.237

6.  Lymphatic filariasis mapping by immunochromatographic test cards and baseline microfilaria survey prior to mass drug administration in Sierra Leone.

Authors:  Joseph B Koroma; Momodu M Bangura; Mary H Hodges; Mohamed S Bah; Yaobi Zhang; Moses J Bockarie
Journal:  Parasit Vectors       Date:  2012-01-11       Impact factor: 3.876

7.  Brugia malayi adult low molecular weight IgG4-reactive antigens induce differential cytokine response in lymphocytes of endemic normal and asymptomatic microfilariae carriers in vitro.

Authors:  Bimal P Mohanty; Ramanuj Lahiri; Shailja Misra-Bhattacharya; Santosh K Kar
Journal:  J Clin Immunol       Date:  2007-03-20       Impact factor: 8.542

8.  Human thelaziasis, Europe.

Authors:  Domenico Otranto; Moreno Dutto
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

9.  Modeling analysis of GST (glutathione-S-transferases) from Wuchereria bancrofti and Brugia malayi.

Authors:  Rayavarapu Bhargavi; Siddharth Vishwakarma; Upadhyayula Suryanarayana Murty
Journal:  Bioinformation       Date:  2005-06-02

10.  The geographical distribution of lymphatic filariasis infection in Malawi.

Authors:  Bagrey Mm Ngwira; Phillimon Tambala; A Maria Perez; Cameron Bowie; David H Molyneux
Journal:  Filaria J       Date:  2007-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.